{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:42:47Z","timestamp":1792212167589,"version":"4.4.0"},"reference-count":57,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.8132-26","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:11:48Z","timestamp":1789423908000},"source":"Crossref","is-referenced-by-count":0,"title":["Pathophysiology and Emerging Therapies in Chronic Inflammatory Demyelinating Polyneuropathy"],"prefix":"10.2169","author":[{"given":"Masaaki","family":"Yoshikawa","sequence":"first","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ide","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Neurology, Saga University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-second revision. Eur J Neurol 28: 3556-3583, 2021.","DOI":"10.1111\/ene.14959"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Koike H, Katsuno M. Pathophysiology of chronic inflammatory demyelinating polyneuropathy: insights into classification and therapeutic strategy. Neurol Ther 9: 213-227, 2020.","DOI":"10.1007\/s40120-020-00190-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Mair D, Madi H, Eftimov F, Lunn MP, Keddie S. Novel therapies in CIDP. J Neurol Neurosurg Psychiatry 96: 38-46, 2025.","DOI":"10.1136\/jnnp-2024-334165"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Dyck PJ, O\u2019Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11: 136-141, 1982.","DOI":"10.1002\/ana.410110205"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dyck PJ, Daube J, O\u2019Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314: 461-465, 1986.","DOI":"10.1056\/NEJM198602203140801"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7: 136-144, 2008.","DOI":"10.1016\/S1474-4422(07)70329-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 11: 493-502, 2012.","DOI":"10.1016\/S1474-4422(12)70093-5"},{"key":"8","unstructured":"8. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17: 35-46, 2018."},{"key":"9","unstructured":"9. Allen JA, Lin J, Basta I, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 23: 1013-1024, 2024."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Caballero-\u00c1vila M, Pascual-Go\u00f1i E, Lleix\u00e0 C, Mart\u00edn-Aguilar L, Collet-Vidiella R, Querol L. The changing landscape of primary autoimmune neuropathies. Nat Rev Neurol 21: 544-555, 2025.","DOI":"10.1038\/s41582-025-01133-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50: 621-637, 1975.","DOI":"10.1016\/S0025-6196(25)09732-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci 27: 427-458, 1976.","DOI":"10.1016\/0022-510X(76)90213-6"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Koike H, Nishi R, Ikeda S, et al. Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology 91: 1051-1060, 2018.","DOI":"10.1212\/WNL.0000000000006625"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ikeda S, Koike H, Nishi R, et al. Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 90: 988-996, 2019.","DOI":"10.1136\/jnnp-2019-320741"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kuwabara S, Isose S, Mori M, et al. Different electrophysiological profiles and treatment response in \u201ctypical\u201d and \u201catypical\u201d chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 86: 1054-1059, 2015.","DOI":"10.1136\/jnnp-2014-308452"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Shibuya K, Tsuneyama A, Misawa S, et al. Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes. J Neuroimmunol 341: 577170, 2020.","DOI":"10.1016\/j.jneuroim.2020.577170"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kuwahara M, Suzuki H, Samukawa M, Hamada Y, Takada K, Kusunoki S. Clinical features of CIDP with LM1-associated antibodies. J Neurol Neurosurg Psychiatry 84: 573-575, 2013.","DOI":"10.1136\/jnnp-2012-303440"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Koike H, Ikeda S, Fukami Y, et al. Complement deposition and macrophage-induced demyelination in CIDP with anti-LM1 antibodies. J Neurol Sci 408: 116509, 2020.","DOI":"10.1016\/j.jns.2019.116509"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol 73: 370-380, 2013.","DOI":"10.1002\/ana.23794"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82: 879-886, 2014.","DOI":"10.1212\/WNL.0000000000000205"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tashiro T, Ogata H, Fukami Y, et al. Clinical, electrophysiologic, and pathologic features of anti-contactin-associated protein 1 autoimmune nodopathy. Neurology 105: e214143, 2025.","DOI":"10.1212\/WNL.0000000000214143"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Koike H, Kadoya M, Kaida KI, et al. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry 88: 465-473, 2017.","DOI":"10.1136\/jnnp-2016-314895"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ogata H, Yamasaki R, Hiwatashi A, et al. Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2: 960-971, 2015.","DOI":"10.1002\/acn3.248"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kadoya M, Kaida K, Koike H, et al. IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: clinical significance and diagnostic utility of a conventional assay. J Neuroimmunol 301: 16-22, 2016.","DOI":"10.1016\/j.jneuroim.2016.10.013"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Dalakas MC. Autoimmune neurological disorders with IgG4 antibodies: a distinct disease spectrum with unique IgG4 functions responding to anti-B cell therapies. Neurotherapeutics 19: 741-752, 2022.","DOI":"10.1007\/s13311-022-01210-1"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Querol L, Rojas-Garc\u00eda R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2: e149, 2015.","DOI":"10.1212\/NXI.0000000000000149"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN; PREDICT. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 78: 1079-1084, 2012.","DOI":"10.1212\/WNL.0b013e31824e8f84"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. van Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 9: 245-253, 2010.","DOI":"10.1016\/S1474-4422(10)70021-1"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Sch\u00e4cke H, D\u00f6cke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96: 23-43, 2002.","DOI":"10.1016\/S0163-7258(02)00297-8"},{"key":"30","unstructured":"30. van Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 17: 35-46, 2018."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Bril V, Hadden RDM, Brannagan TH 3rd, et al. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: the ADVANCE-CIDP 1 randomized controlled trial. J Peripher Nerv Syst 28: 436-449, 2023.","DOI":"10.1111\/jns.12573"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 29: 173-184, 2005.","DOI":"10.1385\/CRIAI:29:3:173"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 119: 1055-1066, 1996.","DOI":"10.1093\/brain\/119.4.1055"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn: the architect behind the immune and nonimmune functions of IgG and albumin. J Immunol 194: 4595-4603, 2015.","DOI":"10.4049\/jimmunol.1403014"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 128: 4372-4386, 2018.","DOI":"10.1172\/JCI97911"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Levine T, Muley S. Early deterioration of CIDP following transition from IVIG to FcRn inhibitor treatment. J Neurol Sci 468: 123313, 2025.","DOI":"10.1016\/j.jns.2024.123313"},{"key":"37","unstructured":"37. Yoshikawa M, Goto Y, Tsutsumi M, et al. Real-world application of subcutaneous efgartigimod in chronic inflammatory demyelinating polyradiculoneuropathy. Intern Med. Forthcoming."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Mouthon L, Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 104 Suppl 1: 3-9, 1996.","DOI":"10.1111\/cei.1996.104.s1.3"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Tai H, Niu S, Pan H, et al. Preliminary observations on the efficacy of efgartigimod therapy in autoimmune nodopathy. Eur J Neurol 32: e70269, 2025.","DOI":"10.1111\/ene.70269"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Guptill JT, Sleasman JW, Steeland S, et al. Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis. Autoimmunity 55: 620-631, 2022.","DOI":"10.1080\/08916934.2022.2104261"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Querol LA, Hartung HP, Lewis RA, et al. The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-targeted therapies. Neurotherapeutics 19: 864-873, 2022.","DOI":"10.1007\/s13311-022-01221-y"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Kanda T. Biology of the blood-nerve barrier and its alteration in immune mediated neuropathies. J Neurol Neurosurg Psychiatry 84: 208-212, 2013.","DOI":"10.1136\/jnnp-2012-302312"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Chen JY, Sanghani N, Palmer K, Li Y, Lin F, Abbatemarco JR. Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies. Front Neurol 16: 1695461, 2025.","DOI":"10.3389\/fneur.2025.1695461"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep 66: 734-737, 2017.","DOI":"10.15585\/mmwr.mm6627e1"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Mathey EK, Park SB, Hughes RA, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. J Neurol Neurosurg Psychiatry 86: 973-985, 2015.","DOI":"10.1136\/jnnp-2014-309697"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Doneddu PE, Cocito D, Fazio R, et al. Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies. J Neurol Neurosurg Psychiatry 95: 838-844, 2024.","DOI":"10.1136\/jnnp-2023-332844"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Nobile-Orazio E, Cocito D, Manganelli F, et al. Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial. Brain 148: 1112-1121, 2025.","DOI":"10.1093\/brain\/awae400"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Huijbers MG, Plomp JJ, van der Maarel SM, Verschuuren JJ. IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders. Ann N Y Acad Sci 1413: 92-103, 2018.","DOI":"10.1111\/nyas.13561"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Neys SFH, Hendriks RW, Corneth OBJ. Targeting Bruton\u2019s tyrosine kinase in inflammatory and autoimmune pathologies. Front Cell Dev Biol 9: 668131, 2021.","DOI":"10.3389\/fcell.2021.668131"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Zhang X, Zhao J, Zhao X, et al. Daratumumab treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a case report. Ann Clin Transl Neurol 13: 622-626, 2026.","DOI":"10.1002\/acn3.70265"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Lin CS, Krishnan AV, Park SB, Kiernan MC. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 68: 862-869, 2011.","DOI":"10.1001\/archneurol.2011.137"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Allen JA, Eftimov F, Querol L. Outcome measures and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathy: from research to clinical practice. Expert Rev Neurother 21: 805-816, 2021.","DOI":"10.1080\/14737175.2021.1944104"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Fukami Y, Iijima M, Koike H, Yamada S, Hashizume A, Katsuno M. Association of serum neurofilament light chain levels with clinicopathology of chronic inflammatory demyelinating polyneuropathy, including NF155 reactive patients. J Neurol 268: 3835-3844, 2021.","DOI":"10.1007\/s00415-021-10537-2"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Ohyama K, Koike H, Katsuno M, et al. Muscle atrophy in chronic inflammatory demyelinating polyneuropathy: a computed tomography assessment. Eur J Neurol 21: 1002-1010, 2014.","DOI":"10.1111\/ene.12426"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Fisse AL, Motte J, Gr\u00fcter T, Sgodzai M, Pitarokoili K, Gold R. Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy. Neurol Res Pract 2: 42, 2020.","DOI":"10.1186\/s42466-020-00088-8"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Michael MR, Wieske L, Allen JA, et al. Inflammatory Neuropathy Consortium base (INCbase): a protocol of a global prospective observational cohort study for the development of a prediction model for treatment response in chronic inflammatory demyelinating polyneuropathy. BMC Neurol 24: 415, 2024.","DOI":"10.1186\/s12883-024-03903-w"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. McCrone P, Chisholm D, Knapp M, et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 10: 687-694, 2003.","DOI":"10.1046\/j.1351-5101.2003.00701.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8132-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:16:28Z","timestamp":1792210588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_8132-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":57,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8132-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"8132-26"}}